Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.4%

8 terminated/withdrawn out of 52 trials

Success Rate

81.4%

-5.1% vs industry average

Late-Stage Pipeline

29%

15 trials in Phase 3/4

Results Transparency

63%

22 of 35 completed trials have results

Key Signals

2 recruiting22 with results8 terminated

Enrollment Performance

Analytics

Phase 2

17(45.9%)

Phase 3

12(32.4%)

Phase 1

4(10.8%)

Phase 4

3(8.1%)

N/A

1(2.7%)

37Total

Phase 2(17)

Phase 3(12)

Phase 1(4)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (52)

Showing 20 of 52 trials

NCT04370522Terminated

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Role: lead

NCT05744375Phase 2Terminated

Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab

Role: lead

NCT07478939Completed

Study on the Level of Physical Activity in Patients Diagnosed With Breast Cancer in Spain

Role: lead

NCT04293393Phase 2Active Not Recruiting

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Role: lead

NCT04603820Active Not Recruiting

Registry Study of Pregnancy and Breast Cancer

Role: lead

NCT05583110Phase 2Terminated

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT07215364Not ApplicableNot Yet Recruiting

Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors

Role: lead

NCT05063786Phase 3Active Not Recruiting

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

Role: lead

NCT03390894Recruiting

Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies

Role: lead

NCT05252988Phase 2Active Not Recruiting

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

Role: lead

NCT05181462Phase 1Active Not Recruiting

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

Role: collaborator

NCT03800355Completed

Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk

Role: lead

NCT02819882Recruiting

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

Role: lead

NCT03205761Phase 2Completed

Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer

Role: lead

NCT02028507Phase 3Completed

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Role: lead

NCT00128310Phase 3Completed

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

Role: lead

NCT01875367Phase 3Completed

Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Role: lead

NCT00121992Phase 3Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Role: lead

NCT00258960Phase 2Completed

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Role: lead

NCT00432172Phase 2Completed

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Role: lead